ARTO: long-term OS of SBRT and abiraterone in oligometastatic prostate cancer

Giulio Francolini, MD, University of Florence, Florence, Italy, discusses long-term overall survival (OS) results from the Phase II ARTO trial (NCT03449719) of stereotactic body radiation therapy (SBRT) with abiraterone acetate and androgen deprivation therapy versus systemic treatment alone in oligometastatic castrate-resistant prostate cancer. The updated analysis demonstrated significant overall survival and prostate cancer-specific survival benefits favoring the combination approach, with no new safety concerns. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.